Lifecore Biomedical, Inc., a contract development and manufacturing organization (CDMO), has finalized a series of updated commercial arrangements with its long-term commercial Hyaluronic Acid and CDMO customer, Alcon to extend and expand the existing relationship.

Additionally, the company also entered into a limited waiver and amendment to its credit agreements with Alcon and with BMO to waive certain financial reporting delivery requirements.

In December of 2023, Lifecore entered into a series of commercial agreements with Alcon, including a long-term 8-year extension of its contract manufacturing agreement for increased capacity of aseptic manufacturing services; an amendment to its Hyaluronic Acid supply agreement to provide Alcon with an option to purchase additional HA equipment to accommodate expected future capacity needs; and new storage services agreement for Lifecore to store certain of Alcon’s HA ingredients that are manufactured by Lifecore.

James Hall, President, and CEO of Lifecore, said, “We are excited to finalize these agreements with our long-term customer, Alcon, which expand our relationship and provide Lifecore additional financial flexibility and opportunities to broaden the scope of support for their portfolio of products.   We believe that these agreements will help facilitate our next chapter of growth together after a successful 40-year relationship, which has been based on trust. This demonstrates how our unique set of capabilities positions us as the partner of choice to help our customers bring their complex innovations to market.”